📰 More Lines News
More Lines News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from More Lines. Real-time updates on events, politics, business and more.
November 23, 2023
The telecommunications landscape in the United States is fiercely competitive, and choosing between Mint Mobile and T-Mobile can be a challenging decision.
June 25, 2023
ARLINGTON, Va. — Last week, yes. every kid. foundation. announced the first-ever class of No More Lines Fellows. Over the rest of this year, these fellows will identify opportunities and
June 21, 2022
21.06.2022 - AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the results from the Phase 3 PROpel trial have been published in NEJM Evidence. Results from the trial showed that LYNPARZA in combination ...
May 10, 2022
10.05.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology ...
March 16, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
March 16, 2022
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer ... | March 16, 2022
March 12, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
March 12, 2022
First and Only Targeted Adjuvant Therapy With FDA-Approved Indication Specifically for Patients With gBRCAm, HER2-Negative High-Risk Early Breast CancerFirst and Only PARP Inhibitor to Show Overall Survival Benefit in Early Breast CancerKENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--AstraZeneca and Merck (NYSE: MRK),...
November 4, 2021
/PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies,...